步长制药：陕西步长药品生产许可证变更

Core Viewpoint - Company has received a new drug production license from the Shaanxi Provincial Drug Administration, allowing for the expansion of its production capabilities and self-manufacturing of certain products, which is expected to positively impact future operations [1] Group 1: License and Production Changes - The company’s subsidiary, Shaanxi Buchang, has obtained a revised drug production license from the Shaanxi Provincial Drug Administration [1] - The license change includes the addition of a tablet production line at the company’s facility located at 16 Buchang Road, Qindu District, Xianyang City, Shaanxi Province [1] - The production of Phosphate Sitagliptin Tablets, previously contracted to Shandong Danhong Pharmaceutical Co., Ltd., will now be produced in-house following compliance with GMP standards [1] Group 2: Impact on Operations - The changes are expected to optimize the company's production structure, ensuring stable production capacity to meet market demand [1] - The overall impact of these changes is anticipated to be positive for the company's future operations [1]